BioCentury
ARTICLE | Clinical News

Tarextumab: Completed Phase Ib/II enrollment

September 5, 2016 7:00 AM UTC

OncoMed completed enrollment of 145 patients with extensive-stage SCLC in the Phase II portion of the double-blind, placebo-controlled, U.S. Phase Ib/II PINNACLE trial of 15 mg/kg IV tarextumab. Patie...